Filtered By:
Drug: Taxotere
Procedure: Radiography
This page shows you your search results in order of date.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: AAP + C was safe with improved rPFS, OS duration, and a higher proportion of PSA declines. This suggests that AAP + C given earlier rather than sequentially may benefit some men. Further work is needed to identify this population.PMID:37582240 | DOI:10.1200/JCO.22.02639
Source: Clinical Prostate Cancer - August 15, 2023 Category: Cancer & Oncology Authors: Susan F Slovin Karen Knudsen Susan Halabi Renee de Leeuw Ayesha Shafi Praneet Kang Steven Wolf Bin Luo Anuradha Gopalan Tracy Curley Mark Fleming Ana Molina Celina Fernandez Kevin Kelly Source Type: research
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
CONCLUSION: Pembrolizumab plus olaparib did not significantly improve rPFS or OS versus NHA in participants with biomarker-unselected, heavily pretreated mCRPC. The study was stopped for futility. No new safety signals occurred.PMID:37290035 | DOI:10.1200/JCO.23.00233
Source: Clinical Prostate Cancer - June 8, 2023 Category: Cancer & Oncology Authors: Emmanuel S Antonarakis Se Hoon Park Jeffrey C Goh Sang Joon Shin Jae Lyun Lee Niven Mehra Ray McDermott N úria Sala-Gonzalez Peter C Fong Richard Greil Margitta Retz Juan Pablo Sade Patricio Yanez Yi-Hsiu Huang Stephen D Begbie Rustem Airatovich Gafanov Source Type: research
A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis
CONCLUSIONS: Our data demonstrate that a combination of BAL and DOC has greater antitumor activity in a model of PCa bone metastases than either drug alone. These data support further evaluation of this combination in metastatic PCa.PMID:37244751 | DOI:10.1002/pros.24584
Source: Cancer Control - May 27, 2023 Category: Cancer & Oncology Authors: Tyler Robinson June Escara-Wilke Jinlu Dai Johann Zimmermann Evan T Keller Source Type: research
Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for prgoression and switch of therapy
Aktuelle Urol. 2023 May 26. doi: 10.1055/a-2055-0869. Online ahead of print.ABSTRACTBased on convincing data with an increase in overall survival (OS), the current national and international European Guidelines (S3, ESMO, EAU) recommend a combination therapy with ADT plus Docetaxel or plus the next-generation antiandrogens abiraterone (plus prednisone/prednisolone), apalutamide or enzalutamide as standard treatment for mHSPC patients with a good performance status (ECOG 0-1). Abiraterone received approval only for use in patients with newly diagnosed (de novo) high-risk mHSPC. There is no restrictive approval status for do...
Source: Aktuelle Urologie - May 26, 2023 Category: Urology & Nephrology Authors: Kurt Miller Source Type: research
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer
CONCLUSION: For mCRPC patients receiving abiraterone or docetaxel, NED and its proportion were critical predictive factors. NED detection at mCRPC might aid in predicting patients' outcomes and optimizing treatment decisions.PMID:36907910 | DOI:10.1007/s00432-023-04639-9
Source: Clinical Prostate Cancer - March 13, 2023 Category: Cancer & Oncology Authors: Nanwei Xu Jinge Zhao Fengnian Zhao Haoyang Liu Wenlian Yin Sha Zhu Ling Nie Guangxi Sun Linmao Zheng Zhenhua Liu Diming Cai Junru Chen Jindong Dai Yuchao Ni Zhipeng Wang Xingming Zhang Jiayu Liang Yuntian Chen Xu Hu Xiuyi Pan Xiaoxue Yin Xudong Zhu Yaowen Source Type: research
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
CONCLUSION: SAKK 08/16 met its primary end point, showing that switch maintenance with darolutamide after prior taxane chemotherapy and at least one ARPI resulted in a statistically significant but clinically modest rPFS prolongation with good tolerability. The median OS with darolutamide maintenance appears promising. Should these findings be confirmed in a larger trial, maintenance treatment could be a novel strategy in managing patients with mCRPC, especially those who responded well to prior ARPI.PMID:36753698 | DOI:10.1200/JCO.22.01726
Source: Clinical Prostate Cancer - February 8, 2023 Category: Cancer & Oncology Authors: Silke Gillessen Giuseppe Procopio Stefanie Hayoz Elo ïse Kremer Michael Schwitter Orazio Caffo David Lorente Augusto Pedrazzini Guilhem Roubaud Soazig Nenan Aurelius Omlin Consuelo Buttigliero Juan Ignacio Delgado Mingorance Ar ánzazu González-Del-Alba Source Type: research
Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in Germany
CONCLUSION: Real-world experiences indicate that favorable oncologic outcomes can be achieved with CAB especially regarding PSA-response and OS even in the fourth line or later in patients with mCRPC.PMID:36244915 | DOI:10.1016/j.urolonc.2022.09.011
Source: Urologic Oncology - October 16, 2022 Category: Urology & Nephrology Authors: Mike Wenzel Angelika Borkowetz Verena Lieb Manuela A Hoffmann Hendrik Borgmann Thomas H öfner Robert Dotzauer Manuel Neuberger Thomas S Worst Jost von Hardenberg Johannes Linxweiler Niklas Kl ümper Source Type: research
